NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world. NeuroPace is located in Mountain View, California.
Neuronetics is a medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. It is the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment.
Nanostim is developing a self-contained leadless cardiac pacemaker system to eliminate the leads and surgical pocket required by conventional pacemakers, thereby removing the associated complications of infection and mechanical lead failure. The Nanostim approach changes pacemaker therapy delivery from a surgical procedure to a less-invasive, simplified catheter-based procedure.
Microfabrica is a developer of micro- and millimeter-scale devices and systems. Its breakthrough process and materials enable the development of Ultra-High Precision™ Parts, SubAssemblies and 3D MicroMachines, which are used in a variety of medical-device, semiconductor-test and aerospace applications.
MicroCHIPS is pioneering intelligent implanted devices designed to improve the health of millions of people with chronic conditions that require careful monitoring and precise therapy. Based on proprietary microreservoir technology first developed at the Massachusetts Institute of Technology, MicroCHIPS' platform incorporates long-term implant technologies and wireless communications, as well as expertise in protein and peptide formulation to address challenging delivery conditions.
Lycera is a biopharmaceutical company pioneering innovative approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting novel pathways to develop new classes of selective, oral immunomodulators for the treatment of patients with diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.
As surgery has rapidly become less invasive, it has driven the need for better illumination and surgical tools. Invuity’s Eigr technology utilizes unique optical structures to deliver light - uniformly and efficiently - to even the smallest surgical fields. This proprietary technology is integrated into surgical tools, providing unprecedented visualization into areas where surgeons struggle to see.
Gynesonics is developing a minimally-invasive, uterine-sparing treatment for fibroid tumors. It is an ultrasound-guided needle ablation device designed for in-office use by the gynecologist.
Founded in 2001 and headquartered in Orange County, California, Glaukos is an ophthalmic medical device company that is committed to transforming the management of open-angle glaucoma. The company is well capitalized to develop and commercialize innovative treatment technologies for glaucoma specialists and general, comprehensive ophthalmic surgeons. Through rigorous scientific and clinical research, Glaukos is developing a portfolio of minimally-invasive micro-bypass stents to improve upon the safety and efficacy outcomes of surgical implant procedures.
Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Its technology enables the rapid, efficient, highly parallel, and reproducible analysis of tens to hundreds of genetic markers across hundreds or thousands of DNA samples in hours instead of days or weeks. The company went public in 2011.